Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?

摘要: Abstract Aim To examine the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for detection bone metastasis in breast cancer patients and assess whether whole body scan (BS) with 99mTc-methylene diphosphonate provides any additional information. Material Methods Study group comprised 150 patients, mean age 52 years (range 27–85) cancer, suspected having metastases. All had undergone both FDG-PET/CT BS or without single photon (SPECT/CT) within a period 6 weeks. The final diagnosis was established by histopathological findings, imaging, clinical follow-up longer than 10 months. Cancer antigen 15-3 (CA15-3) carcinoembryogenic (CEA) were measured all patients. Results Histologically 83%, 7% 10% infiltrating ductal, lobular mixed carcinoma respectively. Confirmed metastases present 86 (57.3%) absent 64 (42.7%). Mean CA15-3 CEA values 74.6 ng/mL 60.4 U/mL respectively, compared to 21.3 ng/mL 3.2 U/mL (p  Conclusion Our findings suggest that is superior SPECT/CT.